# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of...
Rodman & Renshaw analyst Brandon Folkes initiates coverage on Heron Therapeutics (NASDAQ:HRTX) with a Buy rating and ann...
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.
Needham analyst Serge Belanger reiterates Heron Therapeutics (NASDAQ:HRTX) with a Buy and maintains $5 price target.
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(...